Market Cap 257.07M
Revenue (ttm) 198.77M
Net Income (ttm) -18.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9.51%
Debt to Equity Ratio 0.00
Volume 5,045,291
Avg Vol 571,358
Day's Range N/A - N/A
Shares Out 59.10M
Stochastic %K 55%
Beta 0.78
Analysts Strong Sell
Price Target $11.75

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 202 734 3400
Fax: 202 296 1450
Address:
2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States
AWIIII
AWIIII Nov. 18 at 11:00 PM
0 · Reply
Orlandotrader
Orlandotrader Nov. 18 at 10:56 PM
$VNDA Lots MORE to come The FDA will conduct an expedited re-review of the partial clinical hold preventing long term clinical studies of tradipitant for the treatment of motion sickness by November 26, 2025. The FDA will continue its review of Vanda's New Drug Application (NDA) for this indication, with the existing Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025. The FDA will conduct an expedited re-review of Vanda's supplemental New Drug Application (sNDA) for HETLIOZ® for the treatment of jet lag disorder by January 7, 2026, including consideration of alternative or narrowed indications focusing on the sleep-related aspects of jet lag disorder. Bysanti™ NDA for bipolar I disorder and schizophrenia is under review by the FDA with a PDUFA target action date of February 21, 2026.
0 · Reply
dixiebull
dixiebull Nov. 18 at 10:07 PM
watchlist for tomorrow: $BTQ gret play for us nearly to 8, see if 7 holds now for a move through 8 to 8.50/9 $TMC ripped to 6.17 here now, see if 5.50 holds on a dip for a move to 6.17 break to 6.35/6.50/7 $TARA to have a CC Wed and it pushed to 6.85, see if 6 can hold on a dip for a move to break 6.85 for 7 and 7.25 to 7.50 $VNDA slow grind to 5.46, holding 5.35 area, I want 5.25 to hold for a move to 5.50 and 6 $ALT made a move to 4.73, see if 4.50 holds for a move to 5 and 5.25
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 18 at 9:46 PM
$VNDA Trading at $5.35, ranging from $3.92 to $5.61 recently with a peak of 5M shares traded on Nov 18, 2025.
0 · Reply
cntrade1
cntrade1 Nov. 18 at 9:09 PM
$VNDA let’s run 🚀
0 · Reply
topstockalerts
topstockalerts Nov. 18 at 8:47 PM
$VNDA let's close strong.. 🏦
0 · Reply
cntrade1
cntrade1 Nov. 18 at 8:47 PM
$VNDA Ah 👀
0 · Reply
samedison
samedison Nov. 18 at 8:24 PM
$VNDA is next $NVDA
0 · Reply
topstockalerts
topstockalerts Nov. 18 at 8:21 PM
$VNDA Looking good!
0 · Reply
jacckkmm
jacckkmm Nov. 18 at 8:19 PM
$VNDA waiting for some PT PR’s of some financial companies…. Should be fun when they arrive.. and I think they will. Great info on our company today!
0 · Reply
Latest News on VNDA
Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals

Oct 14, 2024, 10:37 AM EDT - 1 year ago

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals


AWIIII
AWIIII Nov. 18 at 11:00 PM
0 · Reply
Orlandotrader
Orlandotrader Nov. 18 at 10:56 PM
$VNDA Lots MORE to come The FDA will conduct an expedited re-review of the partial clinical hold preventing long term clinical studies of tradipitant for the treatment of motion sickness by November 26, 2025. The FDA will continue its review of Vanda's New Drug Application (NDA) for this indication, with the existing Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025. The FDA will conduct an expedited re-review of Vanda's supplemental New Drug Application (sNDA) for HETLIOZ® for the treatment of jet lag disorder by January 7, 2026, including consideration of alternative or narrowed indications focusing on the sleep-related aspects of jet lag disorder. Bysanti™ NDA for bipolar I disorder and schizophrenia is under review by the FDA with a PDUFA target action date of February 21, 2026.
0 · Reply
dixiebull
dixiebull Nov. 18 at 10:07 PM
watchlist for tomorrow: $BTQ gret play for us nearly to 8, see if 7 holds now for a move through 8 to 8.50/9 $TMC ripped to 6.17 here now, see if 5.50 holds on a dip for a move to 6.17 break to 6.35/6.50/7 $TARA to have a CC Wed and it pushed to 6.85, see if 6 can hold on a dip for a move to break 6.85 for 7 and 7.25 to 7.50 $VNDA slow grind to 5.46, holding 5.35 area, I want 5.25 to hold for a move to 5.50 and 6 $ALT made a move to 4.73, see if 4.50 holds for a move to 5 and 5.25
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 18 at 9:46 PM
$VNDA Trading at $5.35, ranging from $3.92 to $5.61 recently with a peak of 5M shares traded on Nov 18, 2025.
0 · Reply
cntrade1
cntrade1 Nov. 18 at 9:09 PM
$VNDA let’s run 🚀
0 · Reply
topstockalerts
topstockalerts Nov. 18 at 8:47 PM
$VNDA let's close strong.. 🏦
0 · Reply
cntrade1
cntrade1 Nov. 18 at 8:47 PM
$VNDA Ah 👀
0 · Reply
samedison
samedison Nov. 18 at 8:24 PM
$VNDA is next $NVDA
0 · Reply
topstockalerts
topstockalerts Nov. 18 at 8:21 PM
$VNDA Looking good!
0 · Reply
jacckkmm
jacckkmm Nov. 18 at 8:19 PM
$VNDA waiting for some PT PR’s of some financial companies…. Should be fun when they arrive.. and I think they will. Great info on our company today!
0 · Reply
1979to2012
1979to2012 Nov. 18 at 8:00 PM
$VNDA people mis-typing $NVDA are buying $VNDA instead. Lol 😂
1 · Reply
cntrade1
cntrade1 Nov. 18 at 7:56 PM
0 · Reply
johnle66
johnle66 Nov. 18 at 7:52 PM
$VNDA huge upside
0 · Reply
Theflash88
Theflash88 Nov. 18 at 7:50 PM
$ALT My GLP-1 friends… Check out $VNDA Lots of upside.. Small market cap.. $11 PT. Just reported good news on a drug to counter nausea and vomiting of $NVO Wegovy. Do your own DD.
3 · Reply
topstockalerts
topstockalerts Nov. 18 at 7:42 PM
$VNDA setting up nicely.. 🍾
0 · Reply
NewbieInvester
NewbieInvester Nov. 18 at 7:42 PM
$VNDA I thought they report tomorrow? 6 trillion market cap now?
0 · Reply
Millie_Seconds
Millie_Seconds Nov. 18 at 7:37 PM
$VNDA if you're not puking anymore, can you still lose the weight?
0 · Reply
buyitall888
buyitall888 Nov. 18 at 7:24 PM
$VNDA omg this is huuge
0 · Reply
Fitness_Finance
Fitness_Finance Nov. 18 at 7:22 PM
$VNDA 600% daily volume. Spike to $8 would be siiiick
0 · Reply
JeanBets
JeanBets Nov. 18 at 7:21 PM
$VNDA 🦍🦍🦍
0 · Reply
topstockalerts
topstockalerts Nov. 18 at 7:06 PM
$VNDA strong consolidation..
0 · Reply
Mike22332233
Mike22332233 Nov. 18 at 6:50 PM
$VNDA UPDATED NUMBERS….. Do the math … The GLP-1 drug overall market is growing rapidly, with forecasts suggesting that the global market could exceed $157 billion market PER YEAR by 2030. … 30%-40% drop out because of vomit and nausea issues … VNDA drug could target a $47 to $63 Billion market PER YEAR by 2030 … would a big pharma pay $1 BILLION for that ???
0 · Reply